Literature DB >> 10918212

Fibrosis in undifferentiated (anaplastic) thyroid carcinomas: evidence for a dual action of tumour cells in collagen type I synthesis.

T Dahlman1, E Lammerts, M Wik, D Bergström, L Grimelius, K Westermark, K Rubin, N E Heldin.   

Abstract

The mechanisms involved in stromal reactions and fibrosis in solid malignant tumours are incompletely understood. In the present study, collagen type I production was investigated in tissues and cell lines derived from human undifferentiated (anaplastic) thyroid carcinomas, a highly aggressive, often fibrotic malignancy with mesenchymal phenotype. In situ hybridization showed the expression of pro-alpha1(I) collagen mRNA throughout the stromal part of the tumours. However, immunofluorescence staining using an anti-pro-collagen type I antibody revealed the synthesis of pro-collagen type I protein mainly in stromal cells juxtaposed to nests of tumour cells. In one out of five tissue samples from human undifferentiated thyroid carcinomas, pro-alpha1(I) collagen mRNA expression was also found in a small number of tumour cells. Several well-characterized cell lines established from undifferentiated thyroid carcinomas, two from tumours included in the present study, expressed both pro-alpha1(I) collagen and prolyl 4-hydroxylase mRNA, and three of these cell lines also synthesized native triple-helical collagen type I. Taken together, these data suggest that stromal fibroblasts are the main producers of collagen type I in anaplastic thyroid tumours. The carcinoma cells seem to play a regulatory role, stimulating the synthesis of collagen type I protein in the surrounding stroma by increasing pro-alpha1(I) collagen mRNA translation. However, collagen type I production by the carcinoma cells might also contribute to the marked desmoplasia commonly seen in these tumours. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10918212     DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH643>3.0.CO;2-W

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  11 in total

1.  Analysis of protein expression in cell microarrays: a tool for antibody-based proteomics.

Authors:  Ann-Catrin Andersson; Sara Strömberg; Helena Bäckvall; Caroline Kampf; Mathias Uhlen; Kenneth Wester; Fredrik Pontén
Journal:  J Histochem Cytochem       Date:  2006-09-06       Impact factor: 2.479

2.  Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells.

Authors:  Xiaoyun Dong; Christopher Korch; Judy L Meinkoth
Journal:  Endocr Relat Cancer       Date:  2011-04-02       Impact factor: 5.678

3.  Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.

Authors:  Laura A Marlow; Stephen D Rohl; James L Miller; Jeffery A Knauf; James A Fagin; Mabel Ryder; Dragana Milosevic; Brian C Netzel; Stefan K Grebe; Honey V Reddi; Robert C Smallridge; John A Copland
Journal:  J Clin Endocrinol Metab       Date:  2018-09-01       Impact factor: 5.958

4.  RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells.

Authors:  Xiaoyun Dong; Waixing Tang; Stephen Stopenski; Marcia S Brose; Christopher Korch; Judy L Meinkoth
Journal:  Endocr Relat Cancer       Date:  2012-07-22       Impact factor: 5.678

5.  Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid Cancer.

Authors:  Jennifer M Johnson; Stephen Y Lai; Paolo Cotzia; David Cognetti; Adam Luginbuhl; Edmund A Pribitkin; Tingting Zhan; Mehri Mollaee; Marina Domingo-Vidal; Yunyun Chen; Barbara Campling; Voichita Bar-Ad; Ruth Birbe; Madalina Tuluc; Ubaldo Martinez Outschoorn; Joseph Curry
Journal:  Semin Oncol       Date:  2015-09-24       Impact factor: 4.929

6.  Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells.

Authors:  Martina Broecker-Preuss; Jan Viehof; Holger Jastrow; Nina Becher-Boveleth; Dagmar Fuhrer; Klaus Mann
Journal:  J Exp Clin Cancer Res       Date:  2015-07-22

7.  Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.

Authors:  Martina Broecker-Preuss; Stefan Müller; Martin Britten; Karl Worm; Kurt Werner Schmid; Klaus Mann; Dagmar Fuhrer
Journal:  BMC Cancer       Date:  2015-03-26       Impact factor: 4.430

8.  Analysis of different components in the peritumoral tissue microenvironment of colorectal cancer: A potential prospect in tumorigenesis.

Authors:  Chao Huang; Hong Liu; Xiuli Gong; Bin Wen; Dan Chen; Jinyuan Liu; Fengliang Hu
Journal:  Mol Med Rep       Date:  2016-08-01       Impact factor: 2.952

9.  A dual mechanism of activation of the Sonic Hedgehog pathway in anaplastic thyroid cancer: crosstalk with RAS-BRAF-MEK pathway and ligand secretion by tumor stroma.

Authors:  Alessia Parascandolo; Mikko O Laukkanen; Nancy De Rosa; Clara Ugolini; Maria Carmela Cantisani; Anna Maria Cirafici; Fulvio Basolo; Massimo Santoro; Maria Domenica Castellone
Journal:  Oncotarget       Date:  2017-12-17

10.  The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells.

Authors:  Martina Broecker-Preuss; Nina Becher-Boveleth; Stefan Müller; Klaus Mann
Journal:  Cancer Cell Int       Date:  2016-04-02       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.